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Polyethylenimine (PEI), a cationic polymer, is one of the most efficient non-viral vectors for transgene therapy.
Decorin (DCN), a leucine-rich proteoglycan secreted by glomerular mesangial cells (MC), is a promising anti-fibrotic
agent for the treatment of glomerulonephritis. In this study, we used PEI–DCN nanocomplexes with different N/P
ratios to transfect MC in vitro and deliver the MC vector with PEI–DCN expressing into rat anti-Thy1.1 nephritis
kidney tissue via injection into the left renal artery in vivo. The PEI–plasmid DNA complex at N/P 20 had the highest
level of transfection efficiency and the lowest level of cytotoxicity in cultured MC. Following injection, the ex vivo
gene was transferred successfully into the glomeruli of the rat anti-Thy1.1 nephritis model by the MC vector with
the PEI–DCN complex. The exogenous MC with DCN expression was located mainly in the mesangium and the
glomerular capillary. Over-expression of DCN in diseased glomeruli could result in the inhibition of collagen IV
deposition and MC proliferation. The pathological changes of rat nephritis were alleviated following injection of the
vector. These findings demonstrate that the DCN gene delivered by the PEI–DNA nanocomplex with the MC vector
is a promising therapeutic method for the treatment of glomerulonephritis.
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Gene therapy is a promising strategy for treatment of in-
heritable or acquired diseases [1-3]. One of the key fac-
tors for successful gene therapy is the development of
safe and efficient gene delivery vectors. Accumulating
data show that one of the most common using non-viral
vectors in vivo and in vitro is polyethylenimine (PEI)
[4,5]. PEI is a highly water-soluble cationic polymer in
which every two carbon atoms are followed by a nitro-
gen atom. Under physiological conditions, approximately
20% of the nitrogens of PEI are protonated and, as a re-
sult, the ionization state of the polymer can be changed
over a broad pH range [6]. The positive charge of PEI
results in effective binding to the negatively charged
plasmid DNA (pDNA), forming a nanoparticle of the
pDNA complex that is small enough to be transported* Correspondence: zzg@shmu.edu.cn
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in any medium, provided the original work is peasily through the cytoplasm and to protect the pDNA
from nuclease degradation [7,8]. PEI has two structural
forms, linear and branched, with various molecular
masses. Some studies have shown that 25 kDa branched
PEI can be used as a gene vector that has many advan-
tages, such as high transfection efficiency, low cytotox-
icity, no immune reaction and easy modification in vitro
[9-11]. PEI has been used successfully in many experi-
ments and clinical trials [4,12]. For example, the intra-
peritoneal injection route of administration of PEI–DNA
is considered to be promising for the treatment of a var-
iety of diseases, including carcinoma of the stomach,
pancreas and ovary [13,14]. Whether by aerosol inhal-
ation or by the intranasal route, the PEI–DNA complex
is potentially useful as a therapeutic approach for many
lung diseases, such as cancer and asthma [15]. Delivery
of the p53 tumor suppressor gene and PEI complex by
aerosol can inhibit lung metastasis induced by a melan-
oma [16]. When administered by the intranasal route,
the IL-4 antisense oligodeoxynucleotides–PEI complexes
are capable of inhibiting IL-4 secretion in a sensitizedOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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to be an effective therapy for asthma [17].
Glomerulosclerosis, the end stage of various progressive
glomerular diseases, is characterized by over-expression
of TGF-β1 and extracellular matrix deposition. Decorin
(DCN) is a leucine-rich proteoglycan secreted by glom-
erular mesangial cells (MC) in kidney. DCN can bind to
TGF-β and neutralize its biological activity, inhibit the
matrix deposition in glomeruli induced by over-
expression of TGF-β1 and, thus, inhibit the development
of glomerulosclerosis. Earlier, we showed that the over-
expression of DCN could inhibit MC growth, promote
cell apoptosis, and down-regulate the protein levels of
TGF-β1 and collagen type IV in vitro [18]. Using the
hemagglutinating virus of Japan; Sendao virus (HVJ)-
liposome method to transfer a DCN plasmid vector into
rat skeletal muscle, Isaka and colleagues found increased
amounts of DCN protein in skeletal muscle and in kid-
ney with a marked therapeutic effect on rat glomerulo-
nephritis [19]. Therefore, DCN is a promising anti-
fibrotic agent for the treatment of glomerulonephritis.
Successful gene therapy is dependent on the choice of
a sensitive gene and a suitable gene vector, and identifi-
cation of the correct target. Therefore, it is essential in
gene therapy research to explore the way of directional
gene delivery to target organ. In a study of glomerular
disease, it is found that the exogenous mesangial cell
transferred into kidney by renal artery injection has a
feature of “homing instinct” and can migrate to the
mesangium of glomeruli. Kim et al. transferred rat MC
with β-galactosidase expressing plasmid as a cell vector
into a rat left kidney. Cells expressing enzyme activity
were located in the glomerular capillary and mesangium
in 80% of the glomeruli 1 day later [20]. This study pro-
vides evidence that transfer of an ex vivo gene to glom-
eruli is feasible and might prove to be a useful tool for
future investigation of glomerular diseases. We thus
used the MC cell vector to deliver a PEI–DCN expres-
sion plasmid into an animal nephritis model for gene
therapy research.
In this study, we used a PEI–DCN nanocomplex as a
gene vector to transfect cultured mesangial cells and
investigated the effect of DCN in vitro. Subsequently, we
transferred the PEI–DCN expressing MC into the left
kidney of a rat anti-Thy1.1 glomerulonephritis model via
left renal artery injection and assessed the feasibility of
gene therapy delivered by a PEI nanocomplex in glom-
erular diseases.
Methods
Polyethylenimine (PEI, branched, 25 kDa) and the
monoclonal antibody to β-actin were purchased from
Sigma-Aldrich (St. Louis, MO). The monoclonal anti-
DCN antibody was from R&D Systems (Minneapolis,MN). The monoclonal anti-vimentin antibody was from
Chamngdao Biotechnology (Shanghai, China). The mono-
clonal antibody to transforming growth factor (TGF) β1
and the rabbit polyclonal antibody to collagen IV were from
Abcam (Cambridge, UK). The monoclonal antibody to
green fluorescent protein (GFP) was from Cell Signaling
Technology (Danvers, MA). The monoclonal antibody to
proliferating cell nuclear antigen (PCNA) was from Santa
Cruz Biotechnology (Santa Cruz, CA). Peroxidase-
conjugated goat anti-mouse IgG and goat anti-rabbit IgG
were from Jackson ImmunoResearch (West Grove, PA).Cell culture and plasmids
Mesangial cells were prepared from the kidney cortex of
male Sprague–Dawley rats as described [21]. Cells main-
tained in Dulbecco’s modified Eagle medium supplemented
with 10% (v/v) fetal bovine serum at 37°C in a humidified
5% (v/v) CO2 atmosphere were used between passages 6
and 10. Plasmid pcDNA3.1A-DCN made in our laboratory
[22] and plasmid pEGFP (Clontech, Mountain View, CA)
were amplified in Escherichia coli and purified by the His-
peed Plasmid Midi Kit (QIAGEN) according to the manu-
facturer’s protocol.Preparation of the PEI–pDNA nanocomplex
Branched 25 kDa PEI and pDNA were each dissolved in
phosphate-buffered saline (PBS, pH 7.4). Equal volumes of
the PEI and pDNA solutions were mixed together to give
PEI nitrogen to pDNA phosphate (N/P) ratios of 1, 5, 10,
15 and 20, shaken for 30 s and then kept at room
temperature for 30 min. The diameter and zeta potential of
the complexes were determined by a laser particle size
analyzer (Nicomp™ 380 PSS, CA).Transfection of PEI–pEGFP or PEI–DCN into MC
pEGFP was used as a reporter gene to monitor gene ex-
pression. The preparation of PEI–pEGFP complexes at vari-
ous N/P ratios is described in the preceding section. At
24 h before transfection, mesangial cells were seeded into
6-well plates at a density of 3× 105 cells/well. At the time of
transfection, the cells were washed twice with PBS, 200 μl
mixture solution containing 4 μg PEI–pEGFP complex was
added to each well followed by incubation for 6 h at 37°C,
the transfection agent then was replaced by fresh DMEM
containing 10% (v/v) fetal bovine serum and the cells were
incubated for 48 h at 37°C. Transfection of pEGFP with
Lipofectamine™ 2000 (Invitrogen, Carlsbad) prepared
according to the manufacturer’s protocol was used as a
positive control. At 48 h following transfection, expression
of GFP in transfected cells was observed by inverted fluor-
escence microscopy. Cells were harvested and used to
quantify the transfection efficiency of PEI by flow cytometry
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experiments were done in triplicate.
MC were grown as described in the preceding section
and treated with PEI–pDCN complex at an N/P ratio of
20. At 3 days after transfection, geneticin (G418, Sigma)
at a concentration of 0.6 mg/ml was added to the cells.
Three weeks later, positive clones were detected by
Western blotting after culture expansion.
Cytotoxicity
MC cells were seeded in 96-well plates at a density of
8 × 103 cells/well before transfection and incubation for
24 h at 37°C. The cells were transfected by PEI–pEGFP
at different N/P ratios as described above and incubated
for another 48 h at 37°C. Cells treated with naked plas-
mid were used as a negative control. The cells were
transfected with Lipofectamine™ 2000 as a positive con-
trol. Cytotoxicity was assessed using the Cell Counting
Kit8 (Dojindo, Tokyo, Japan) according to the manufac-
turer’s instructions. Relative cell viability was calculated
as:
Cell viability %ð Þ ¼ OD450ðsampleÞ=OD450ðcontrolÞ  100
Western blotting
Cells were harvested in lysis buffer (20 mM Tris at pH
8.0, 150 mM NaCl, 1% (v/v) Nonidet P-40, 1 mM phe-
nylmethylsulfonyl fluoride (PMSF), 1 mM Na3VO4,
1 mM NaF and 1 μg/ml each of aprotinin, leupeptin and
pepstatin) on ice. Proteins (700 μg) of were separated by
SDS-PAGE (10% (w/v) polyacrylamide gel) and trans-
ferred onto a polyvinylidene fluoride membrane. After
blocking with 5% non-fat milk, the membrane was
probed with the appropriate primary antibody overnight
on a shaker at 4°C and proteins were detected by
enzyme-linked chemiluminescence using an ECL kit
(Thermo Scientific, Rockford, IL).
Cell cycle
Analysis of the cell cycle was done by flow cytometry.
MC were digested from culture plates by 0.05% (w/v)
trypsin and treated with citrate buffer for 30 min, then
incubated with RNase for a few minutes followed by
addition of propidium iodide for 15 min. The results
were analyzed by CellQuest software (BD Bioscience,
Mississauga, Ontario, Canada) at the Institute of Bio-
chemistry and Cell Biology, Chinese Academy of
Sciences.
In vivo experimental design
A rat anti-Thy1.1 glomerulonephritis model was made
by injection of rabbit anti-rat thymocyte serum (ATS)
into the tail vein of male Sprague–Dawley rats asdescribed [23]. At day 3, the rats were anesthetized by
an intraperitoneal injection of 10% (w/v) chloral hydrate
(0.4 ml/100 g body weight). The left kidney was exposed
through a left flank incision, the renal artery was sepa-
rated and blood flow was interrupted by vessel clamping.
MC with PEI–PEGFP or PEI–DCN were trypsinized,
suspended in 800 μl of PBS with cell concentration
1 × 106, and injected into the left renal artery using a 29-
gauge needle at a rate of 70 μl/s. The cells remained in
the left kidney for 5 min and then the blood was allowed
to re-perfuse. For the control group, normal mesangial
cells were injected into the left renal artery. After 1, 3
and 5 days, 10 rats from the control group and 10 rats
from each time group of the experimental group were
sacrificed, and both left and right kidneys from each rat
were removed separately.
Immunohistochemistry
Paraffin-embedded (5 μm thick) sections were deparaffi-
nized and endogenous peroxidase was quenched with
3% (v/v) H2O2. The antigen retrieval was done by micro-
wave at 600 power 10 min, in 0.1 M citric acid-sodium
citrate buffer, pH 6.0. Non-specific binding was blocked
using 5% (v/v) normal sheep serum for 30 min at 37°C.
Sections were then incubated with primary antibodies
(anti-EGFP 1:100, anti-DCN 1:200, anti-vimentin 1:50,
anti-PCNA 1:100, anti-collagen IV 1:50) at 4°C over-
night. Immobilized antibodies were detected by the
avidin/biotin/peroxidase technique (Vectastain ABC
Kits, Vector Laboratories, UK). Diaminobenzidine was
used as the chromogen and hematoxylin was used as the
nuclear counterstain. The primary antibody was replaced
by PBS in the negative control.
Statistical analysis
We selected five different glomeruli from each slide at
random for the evaluation of staining results. The posi-
tive area of each glomerulus was measured by
computer-assisted image analysis (KS400, Zeiss,
Germany). All values are expressed as mean ± SD.
Results were analyzed by Student’s t-test with statistically
significant difference set at P ≤0.05.
Results and discussion
It has been reported that the N/P ratio can influence the
efficiency of nanoparticle transfection in vitro [24]. To
identify the optimal transfection conditions, pEGFP was
used as a reporter and PEI–pEGFP nanocomplexes with
different N/P ratios were prepared. The particle size and
the zeta potential of PEI–pEGFP nanocomplexes were
examined (Figure 1). We found the diameter of the
nanocomplex increased from N/P 1 to N/P 5 and then
decreased from N/P 5 to N/P 20, while the zeta potential
of nanocomplexes indicated positive charges increased
Figure 1 Particle size (A) and zeta potential (B) of PEI–pDNA
complexes at different N/P ratios. Data are expressed as the
mean and standard error of at least three separate measurements.
Figure 2 Evaluation of the transfection efficiency in MC with
PEI–pEGFP complexes. A, Fluorescence micrograph of MC
transfected with PEI–pEGFP complexes for 48 h at different N/P
ratios. (a) MC were transfected with Lipofectamine™ 2000 as a
positive control. (b) N/P 1, (c) N/P 5, (d) N/P 10, (e) N/P 15 and (f)
N/P 20. (×100) B, The transfection efficiency of MC with different
N/P ratios was evaluated by flow cytometry. Cells treated with naked
plasmid were used as a negative control. C, Cytotoxicity analysis of
MC with different N/P ratios by the MTT test. Cells treated with
naked plasmid were used as a negative control and cells transfected
with Lipofectamine™ 2000 were used as a positive control. *P <0.01
vs control. The results are representative of at least three similar
experiments.
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report by Ogris [24]. Quantitative analysis of transfection
was done with an inverted fluorescence microscope after
48 h. The results showed that transfection efficiency
increased with N/P ratios from 1–20 and peaked at 20
with a smaller diameter, the expression of EGFP
fluorescence was highest and nearly equal to that
achieved by Lipofectamine™-mediated gene delivery
(Figure 2A). We used flow cytometry to further
estimate the transfection efficiency and the result was
the same as that described above (Figure 2B). Moreover,
the 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) test showed that cell viability was a little lower in
cell groups of N/P 1–20, but there was no significant
difference in cell viability between the control cells and
each group of transfected cells with N/P 1 – 20. However,
cell viability was decreased significantly in the N/P 25
group. The group of Lipofectamine™-transfecting cell also
had significant cytotoxicity (Figure 2C). The PEI–pDNA
complex at an N/P ratio of 20 has the highest transfection
efficiency and the lowest cytotoxicity in cultured MC.
The deliverer for gene therapy generally has two
forms, viral and nonviral. Currently, PEI has emerged as
a potent nonviral vector for gene therapy in vitro and
in vivo. The vehicle with efficient DNA condensation
has been used successfully to transfer genes into living
cells [25-27]. It has been shown that the N/P ratio influ-
ences the efficiency of the gene delivery system and
cytotoxicity dramatically, and the optimal N/P ratio dif-
fers between cell lines [28,29]. Therefore, it is important
to select an optimal N/P ratio of a PEI nanoparticle. In
this study, the PEI–pEGFP complexes showed the high-
est transfection efficiency and relatively lower cytotox-
icity at an N/P ratio of 20.
To investigate the effect of PEI–pDCN on MC biology,
we transfected a PEI–pDCN nanocomplex into cultured
rat MC at N/P 20, which led to over-expression of DCN
in MC (Figure 3A). Western blotting (Figure 3B) showedthat the protein level of DCN in D6 increased signifi-
cantly, whereas the expression of TGF-β1 and collagen
IV decreased markedly compared to the control cells.
The results suggest that over-expression of DCN could
Figure 3 DCN over-expression inhibited expression of TGF-β1
and collagen IV in MC. A, The protein level of DCN was assessed
by Western blotting in PEI–pDCN transfected MC. Normal mesangial
cells were used as a control. D1–D6 are different cell clones. B, The
relative levels of DCN, TGF-β1 and collagen IV protein were
determined by Western blotting in D6. Lanes 1, normal mesangial
cells; 2, pcDNA3.1A-transfected MC; and 3, DCN-transfected MC (D6).
Data are presented as mean± SD. *P <0.01 vs MC and
MC/pcDNA3.1A. The experiment was done at least three times.
Sun et al. Nanoscale Research Letters 2012, 7:451 Page 5 of 9
http://www.nanoscalereslett.com/content/7/1/451inhibit the expression of TGF-β1 and collagen IV of MC
in vitro.
To further examine whether over-expression of DCN
affects the growth of MC, cell cycle analysis of D6 cells
and control cells was done by flow cytometry and the
results showed that D6 cells in the G0/G1 and S phases
were 84.47 ± 1.05% and 5.26 ± 0.51%, respectively. Com-
pared to the controls, the difference was significant
(Table 1). These data indicate that over-expression of
DCN could suppress cell growth by arresting MC in the
G0/G1 phase.Table 1 Analysis of cell cycle in transfected MC by Flow
Cytometry
Groups G0/G1 (%) G2/M (%) S (%)
MC 74.61 ± 3.76 12.06 ± 0.92 13.32 ± 2.03
MC/pcDNA3.1A 75.48 ± 4.17 12.14 ± 1.43 12.37 ± 2.1
D6 84.47 ± 1.05* 10.53 ± 2.79 5.26 ± 0.51*
*P < 0.05 vs MCs and MC/pcDNA3.1A.We used pEGFP as a reporter gene and prepared sta-
bly transfected MC with PEI–pEGFP complexes to es-
timate the glomerular targeting of the MC vector. We
injected MC vector into the normal rat kidney via the
left renal artery and the rats were sacrificed after
2 days. Immunohistochemistry showed that about
65 ± 2.13% of the glomeruli in the left kidney were
positive for EGFP staining and these cells were located
mainly in the mesangium and the glomerular capillary
(Figure 4B), whereas the right kidney of the same animal
was negative for EGFP and served as the control
(Figure 4A). Subsequently, the MC vector with PEI–
DCN was also injected into the normal rats kidney.
Immunohistochemical staining for exogenous DCN
expressing cells had the same localization in glomeruli
as EGFP (Figure 4C), which is consistent with the
distribution pattern of vimentin-positive cells that is
recognized as a mesangial cell marker in glomeruli
(Figure 4D) [30]. By contrast, DCN staining was nega-
tive in the normal kidney where DCN was expressed
at very low or even undetectable levels.
The rat anti-Thy1.1 glomerulonephritis model was
induced by injection of rabbit anti-thymocyte serum
into tail veins. The proliferation of MC and matrix in
mesangium occurred 3 days after injection and more
severe changes were seen at day 7.
Furthermore, the rat models were treated by MC (D6)
vector with PEI–pDCN via injection of the left renal
artery. Immunohistochemistry showed the DCN expres-
sion of D6 cells was located in glomeruli 1 day after the
injection; its expression level was enhanced at day 3 and
decreased slightly at day 5. However, the expression of
DCN in all groups was significantly higher than that in
the uninjected (right) kidney; DCN expression was
totally absent from the uninjected control kidneys
(Figure 5A and B).
The expression of collagen type IV and PCNA in the
glomeruli was detected by immunohistochemical
staining and the results showed that the expression
levels of both collagen type IV and PCNA in glomeruli
in the PEI–pDCN group were decreased significantly
compared to that in uninjected kidneys (Figure 5A and
B). Thus, matrix synthesis and cell proliferation were
inhibited effectively by DCN over-expression in D6 cells.
Efficient targeted gene therapy in vivo is still a major
challenge. PEI is one of the most efficient nonviral
vectors but there are still many problems limiting its
systemic application following intravenous administra-
tion in vivo [31]. For example, the PEI–DNA complex
is restricted by a shortage of organ targeting; it is usu-
ally expressed and aggregates in lung tissue via rat tail
vein injection [32,33]. Cationic polymers and DNA are
known to bind serum proteins, which might serve to
opsonize the complexes and perhaps promote rapid
Figure 4 Location of PEI–pEGFP or PEI–DCN in injected glomeruli. At 48 h after injection of the MC vector with PEI–pEGFP or PEI–DCN,
paraffin sections of kidney were prepared and examined by immunohistochemistry. (A) Normal control glomerulus negative for EGFP staining. (B)
Glomerulus of injected kidney with PEI–pEGFP expressing MC, the results show EGFP-positive cells are located mainly in the mesangial area and a
few epithelial cells of the proximal tubule. (a,b ABC, ×100) (C) Glomerulus of injected kidney with PEI–DCN expressing MC. The exogenous
DCN-positive cells have the same localization as EGFP in glomeruli. (D) Glomerulus of injected kidney with PEI–DCN expressing MC. The vimentin-
positive MC are distributed mainly in the mesangium of glomeruli, which is consistent with the distribution pattern of PEI-DCN positive cells
(c,d ABC× 200).
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Therefore, the recent trial of PEI delivery of genes to
target cells in vivo were done mainly by direct injection
either into the target tissue [13,14,37] or into its blood
supply [38,39] or by introduction with an appropriate
cell vector [20].
PEI-mediated gene delivery to rat kidney was
reported by Boletta et al. [38]. The PEI–DNA particles
injected into the left kidney via the left renal artery
were localized exclusively in the proximal tubule, sug-
gesting that direct injection with PEI–DNA complexes
in kidney could be an effective route for renal tubu-
lointerstitial injury instead of glomerular diseases. Fur-
thermore, the ex vivo trial using a mesangial cell as a
vector to transfer PEI–DNA is more successful for spe-
cific targeting of glomeruli [20]. With the homing in-
stinct of a cell vector, MC with β-galactosidase plasmid
injected into the left kidney via the renal artery were
located and enzyme expressed mainly in the glomeruli
capillary and mesangium. This is a good example of at-
tractive targeting strategy for transgene therapeutics ofglomerular diseases. In this study, we transferred the
MC vector with the PEI–DCN complex into the kid-
ney of rat anti-Thy1.1 nephritis. The results showed
that the exogenous MC with DCN expressing were
located mainly in the mesangium and the glomerular
capillary. Rat anti-Thy1.1 nephritis models are charac-
terized by MC proliferation accompanied with ECM
deposition. Over-expression of DCN in diseased
glomeruli by injection of MC with a PEI–DCN com-
plex could alleviate the pathological changes of rat
nephritis. Thus, the DCN gene delivered by a PEI–
DNA nanocomplex with the MC vector is proved to
be a promising therapeutic reagent for the treatment
of glomerulonephritis.
Conclusions
This study demonstrated that PEI-mediated DCN gene
transfer to MC is effective and could be used as a
gene-stable transfection carrier in vitro. We transferred
a PEI–DCN complex into the glomeruli of a rat anti-
Thy1.1 nephritis model by the MC vector with the
Figure 5 Immunohistochemistry results of DCN, collage IV and PCNA in rat Thy1.1 glomerulonephritis. Immunostaining of (A) DCN, (B)
collage IV and (C) PCNA in rat Thy1.1 glomerulonephritis. (a–d) DCN expression in glomerulus of uninjected kidney. (e–h) DCN-positive
distribution in glomerulus 1, 3 and 5 days after injection with PEI–DCN. Level of collagen IV expression in glomerulus of (i–l) uninjected kidney
and (m–p) injected kidney. PCNA protein level in glomerulus of (q–t) uninjected kidney and (u–x) injected kidney. (ABC× 200).
B, Immunohistochemistry results and statistical analysis. ?, P <0.05 vs uninjected side; *, P <0.01 vs uninjected side; ▲, P <0.05 vs control;
◆, P <0.01 vs control.
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tery. We observed expression of the DCN protein in
transfected MC in injected glomeruli, which have an
important antagonistic effect on glomerular lesion ofrat anti-Thy1.1 nephritis. We have shown the ex vivo
gene transfer of a PEI–DCN complex to glomeruli is
feasible and could be a useful method for gene therapy
of glomerular diseases.
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